Atezolizumab is currently regarded as an effective treatment option for NSCLC (8), and its mechanism of action is different from other inhibitors; this kind of monoclonal antibody directly binds to programmed cell death ligand 1 (PD-L1), promoting double blockade of B7 and programmed cell death protein 1 (PD-1) receptors, thereby restoring anticancer immunity (9). The gene discussed is CD274; the disease is non-small cell lung carcinoma.